Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs

Sabrina Lyngbye Wendt; Carsten Boye Knudsen; John Bagterp Jørgensen; Henrik Madsen; Ahmad  Haidar

Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs

Sabrina Lyngbye Wendt, Carsten Boye Knudsen, John Bagterp Jørgensen, Henrik Madsen, Ahmad Haidar

Research output: Contribution to conference › Poster › Research › peer-review

444 Downloads (Pure)

Abstract

Zealand Pharma has invented a glucagon analogue, ZP-GA-1, with increased stability in liquid formulation for treatment of hypoglycemia. A pharmacodynamic (PD) model is needed to compare ZP-GA-1 with marketed glucagon. We aim to develop a model of the complex glucose-insulin-glucagon dynamics based on physiology and data.

Original language	English
Publication date	2016
Number of pages	1
Publication status	Published - 2016
Event	9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016) - Milan, Italy Duration: 3 Feb 2016 → 6 Feb 2016 Conference number: 9 http://www.attd2016.com/

Conference

Conference	9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016)
Number	9
Country/Territory	Italy
City	Milan
Period	03/02/2016 → 06/02/2016
Internet address	http://www.attd2016.com/

Bibliographical note

Poster Id: ATTD-0146

Access to Document

Poster attd2016 slw final paperFinal published version, 361 KB

http://post-congress.dasterminal.com/attd2016/

OpenUrl availability

Full text

Cite this

Wendt, S. L., Boye Knudsen, C., Jørgensen, J. B., Madsen, H., & Haidar, A. (2016). Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs. Poster session presented at 9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016), Milan, Italy. http://post-congress.dasterminal.com/attd2016/

@conference{53d1edd38bc64d8daf0a3fb68eed5658,

title = "Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs",

abstract = "Zealand Pharma has invented a glucagon analogue, ZP-GA-1, with increased stability in liquid formulation for treatment of hypoglycemia. A pharmacodynamic (PD) model is needed to compare ZP-GA-1 with marketed glucagon. We aim to develop a model of the complex glucose-insulin-glucagon dynamics based on physiology and data.",

author = "Wendt, {Sabrina Lyngbye} and {Boye Knudsen}, Carsten and J{\o}rgensen, {John Bagterp} and Henrik Madsen and Ahmad Haidar",

note = "Poster Id: ATTD-0146; 9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016), ATTD ; Conference date: 03-02-2016 Through 06-02-2016",

year = "2016",

language = "English",

url = "http://www.attd2016.com/",

}

Wendt, SL, Boye Knudsen, C, Jørgensen, JB , Madsen, H & Haidar, A 2016, 'Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs', 9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016), Milan, Italy, 03/02/2016 - 06/02/2016. <http://post-congress.dasterminal.com/attd2016/>

Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs. / Wendt, Sabrina Lyngbye; Boye Knudsen, Carsten; Jørgensen, John Bagterp et al.
2016. Poster session presented at 9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016), Milan, Italy.

Research output: Contribution to conference › Poster › Research › peer-review

TY - CONF

T1 - Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs

AU - Wendt, Sabrina Lyngbye

AU - Boye Knudsen, Carsten

AU - Jørgensen, John Bagterp

AU - Madsen, Henrik

AU - Haidar, Ahmad

N1 - Conference code: 9

PY - 2016

Y1 - 2016

N2 - Zealand Pharma has invented a glucagon analogue, ZP-GA-1, with increased stability in liquid formulation for treatment of hypoglycemia. A pharmacodynamic (PD) model is needed to compare ZP-GA-1 with marketed glucagon. We aim to develop a model of the complex glucose-insulin-glucagon dynamics based on physiology and data.

AB - Zealand Pharma has invented a glucagon analogue, ZP-GA-1, with increased stability in liquid formulation for treatment of hypoglycemia. A pharmacodynamic (PD) model is needed to compare ZP-GA-1 with marketed glucagon. We aim to develop a model of the complex glucose-insulin-glucagon dynamics based on physiology and data.

M3 - Poster

T2 - 9th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2016)

Y2 - 3 February 2016 through 6 February 2016

ER -

Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs

Abstract

Conference

Bibliographical note

Access to Document

OpenUrl availability

Fingerprint

Cite this